NEWS & MEDIA
Stemtek Therapeutcis is one of the top 8 innovations of May!
This spotlight gives us the opportunity to get the word out about us and our work towards accelerating early drug discovery. - May 22, 2017
Scientist is a web-based marketplace that connects the scientific community by providing easy access to information of different suppliers, researchers and enterprises. They are on the cutting edge of innovation happening in the industry and this month CELL2SPHERE™ has been selected as one of the top 8 innovation picks that represents the most ground breaking technologies on the planet.
This spotlight gives us the opportunity to get the word out about us and our work towards accelerating early drug discovery with enhanced biological relevance assays 3D-based cell cultures. With this goal we created Cell2Sphere™, a ready to use 3D cell culture kit will help advance drug development projects by providing a fast, biologically relevant and easy to use tool to screen the activity of test compounds in 3D cell culture. It is delivered frozen for flexible and convenient experiment planning. We at StemTek are so convinced that Cell2Sphere will help advance significantly cancer therapeutics research. These spheroids are grown from cancer stem cell enriched cultures, as a surrogate model for tumor formation. Cell2Sphere™ technology allows study cell-cell interactions, cell signaling mechanisms, and allows for the preservation of metabolic gradients. The result is more comprehensive, accurate, and reproducible data helping scientists achieve drug discovery success.
Founded in 2013, StemTek is a biotech startup entirely dedicated to cancer cell research and drug discovery. StemTek uses 3D cell based assay automated for HTS, allowing the company to test thousands of compounds that target cancer stem cells to stop spheroid formation. 3D cell culture systems allow for stronger, more efficient and reliable drug screening. StemTek collaborates with pharmaceutical and biotech companies to accelerate early stage drug screening to develop new anticancer therapies. With over thirty years combined experience in molecular and cellular oncology, StemTek’s goal is to find treatments that put an end to relapse.
More Last updates
- Stemtek, one of the most powerful 50 entrepreneurs start ups
- El Correo newspaper wrote about StemTek Therapeutics
- A new dimension
- StemTek technology at the EiTB Teknopolis show (TV)
- StemTek is Heading to Boston for MassChallenge!
- Stemtek Therapeutics will attend 3D Cell Culture Congress in London
- An exciting year ahead
- Cancer Stem Cells Impact on Treatment, Obergurgl
- Overcoming the Valley of Death in Emerging Biotechs
- [Spanish] La inhibición terapéutica de la vía de RANK disminuye la recurrencia del cáncer de mama al inducir la diferenciación de las células tumorales